Stay updated on Alpha Study: Afatinib & Pembrolizumab in HNSCC Clinical Trial
Sign up to get notified when there's something new on the Alpha Study: Afatinib & Pembrolizumab in HNSCC Clinical Trial page.

Latest updates to the Alpha Study: Afatinib & Pembrolizumab in HNSCC Clinical Trial page
- Check7 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference2%
- Check14 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
- Check21 days agoNo Change Detected
- Check29 days agoChange DetectedDifference0.1%
- Check36 days agoChange DetectedThe website has updated the 'type of intervention' feature from version v2.13.3 to v2.14.0, indicating a significant change in its functionality.SummaryDifference0.3%
- Check65 days agoChange DetectedThe website has been updated from version 2.13.2 to 2.13.3.SummaryDifference0.1%
- Check72 days agoChange DetectedThe website has updated the contact details section for the study, now providing clearer information on who to contact for questions and where the study is taking place, reflecting a revision from v2.12.2 to v2.13.2.SummaryDifference3%
Stay in the know with updates to Alpha Study: Afatinib & Pembrolizumab in HNSCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Alpha Study: Afatinib & Pembrolizumab in HNSCC Clinical Trial page.